Update of the Mexican College of Rheumatology Guidelines for the Pharmacological Treatment of Rheumatoid Arthritis, 2018

被引：13

作者：

Cardiel, Mario H. ^{[1
]}

Carrillo, Sandra ^{[2
]}

Perez, Marcela ^{[3
]}

Andrade, Lilia ^{[4
]}

Pacheco Tena, Cesar ^{[5
]}

Silveira, Luis H. ^{[6
]}

Limon, Leonardo ^{[7
]}

Cerpa, Sergio ^{[8
]}

Gutierrez Urena, Sergio ^{[8
,9
]}

Duran, Sergio ^{[9
,10
]}

Irazoque Palazuelos, Fedra ^{[4
]}

Munoz Lopez, Sandra ^{[4
]}

Sicsik Ayala, Sandra Araceli ^{[11
]}

Barile, Leonor ^{[12
]}

Ramos Sanchez, Maria Azucena ^{[13
]}

Grajeda Portes, Daniel ^{[13
]}

Portela, Margarita ^{[14
]}

Hernandez Bedolla, Alina ^{[14
]}

Luis Garcia-Figueroa, Jose ^{[15
]}

Montero, Mauricio ^{[16
]}

Abud-Mendoza, Carlos ^{[17
]}

Martinez Martinez, Marco Ulises ^{[17
]}

Herrera van Ostdam, David ^{[17
]}

Pascual-Ramos, Virginia ^{[18
]}

Merayo-Chalico, Javier ^{[18
]}

Guzman-Sanchez, Istar ^{[19
]}

Esther Perez-Bastidas, Maria ^{[20
]}

Aguilar Arreola, Jorge Enrique ^{[21
]}

Lopez Rodriguez, Alejandra ^{[22
]}

Reyes-Cordero, Greta ^{[23
]}

Ricardez, Humberto Alfredo ^{[24
]}

Hernandez Cabrera, Maria Fernanda ^{[25
]}

Olvera-Soto, Guadalupe ^{[26
]}

Xibille Friedmann, Daniel ^{[27
]}

机构：

[1] Ctr Invest Clin Morelia, Morelia, Michoacan, Mexico

[2] Hosp Reg 1ro Octubre, Ciudad De Mexico, Mexico

[3] Inst Mexicano Seguro Social IMSS, Coordinac Invest, Ciudad De Mexico, Mexico

[4] ISSSTE, CMN Noviembre 20, Serv Reumatol, Ciudad De Mexico, Mexico

[5] Univ Autonoma Chihuahua, Fac Med, Chihuahua, Mexico

[6] Inst Nacl Cardiol Ignacio Chavez, Dept Reumatol, Ciudad De Mexico, Mexico

[7] Jefatura Ensetianza & Invest Hosp Cent Norte PEME, Ciudad De Mexico, Mexico

[8] Hosp Civil Guadalajara Fray Antonio Alcalde, Serv Reumatol, Guadalajara, Jalisco, Mexico

[9] Univ Guadalajara, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico

[10] Clin Invest Reumatol & Obesidad, Guadalajara, Jalisco, Mexico

[11] Hosp Especialidades 71, Unidad Med Alta Especialidad UMAE, Torreon, Coahuila, Mexico

[12] Hosp Angeles Pedregal, Ciudad De Mexico, Mexico

[13] Hosp Especialidades IMSS, Unidad Med Alta Especialidad 25, Monterrey, Nuevo Leon, Mexico

[14] Hosp Especialidades CMN Siglo XXI, IMSS, Ciudad De Mexico, Mexico

[15] Colegio Mexicano Reumatol AC, Ciudad De Mexico, Mexico

[16] Hosp Angeles, Hosp Reg ISSSTE, Puebla, Mexico

[17] Univ Autonoma San Luis Potosi, Unidad Invest Reumatol, Hosp Cent Dr Ignacio Morones Prieto, Fac Med, San Luis Potosi, San Luis Potosi, Mexico

[18] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Inmunol & Reumatol, Ciudad De Mexico, Mexico

[19] Ctr Med Inst Seguridad Social Estado Mexico & Mun, Toluca, Estado De Mexic, Mexico

[20] Colegio Jalisciense Reumatol, Guadalajara, Jalisco, Mexico

[21] Hosp Civil Guadalajara Dr Juan I Menchaca, Guadalajara, Jalisco, Mexico

[22] Ctr Invest Enfermedades Autoinmunes, Dermatol Country, Guadalajara, Jalisco, Mexico

[23] Hosp Angeles Chihuahua, Chihuahua, Mexico

[24] Univ Juarez Autonoma Tabasco, Div Acad Ciencias Salud, Ctr Especialidades Med, Inst Seguridad Social Estado Tabasco, Villahermosa, Tabasco, Mexico

[25] Hosp Gen Reg 220 IMSS, Toluca, Estado De Mexic, Mexico

[26] Comis Nacl Protecc Social Salud, Ciudad De Mexico, Mexico

[27] Serv Salud Morelos, Dept Invest & Capacitac, Cuernavaca, Morelos, Mexico

来源：

REUMATOLOGIA CLINICA | 2021年 / 17卷 / 04期

关键词：

Rheumatoid arthritis; Recommendations; Treatment; Therapeutic strategy and vaccination; MODIFYING ANTIRHEUMATIC DRUGS; LONG-TERM SAFETY; ANTITUMOR NECROSIS FACTOR; LOW DISEASE-ACTIVITY; HEAD-TO-HEAD; LATENT TUBERCULOSIS INFECTION; ANTI-TNF AGENTS; CERTOLIZUMAB PEGOL; PREGNANCY OUTCOMES; TARGET STRATEGY;

D O I：

10.1016/j.reuma.2019.04.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Therapeutic advances in rheumatoid arthritis require periodic review of treatment guidelines. Objective: To update the Mexican College of Rheumatology guidelines on the pharmacological treatment of rheumatoid arthritis. Method: Board certified rheumatologists from different health institutions and regions of the country participated. Work teams were formed that reviewed the previous guidelines, elaborated new questions, reviewed the literature, and scored the evidence that was presented and discussed in plenary session. The conclusions were presented to infectologists, gynaecologists and patients. Recommendations were based on levels of evidence according to GRADE methodology. Results: Updated recommendations on the use of available medications for rheumatoid arthritis treatment in Mexico up to 2017 are presented. The importance of adequate and sustained control of the disease is emphasized and relevant safety aspects are described. Bioethical conflicts are included, and government action is invited to strengthen correct treatment of the disease. Conclusions: The updated recommendations of the Mexican College of Rheumatology on the pharmacological treatment of rheumatoid arthritis incorporate the best available information to be used in the Mexican health care system. (C) 2019 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.

引用

页码：215 / 228

页数：14

共 157 条

[1]

Aaltonen KJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030275, 10.1371/journal.pone.0043508]

[2] Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy [J].

Aaltonen, Kalle Jyri ;

Joensuu, Jaana Tuulikki ;

Virkki, Liisa ;

Sokka, Tuulikki ;

Aronen, Pasi ;

Relas, Heikki ;

Valleala, Heikki ;

Rantalaiho, Vappu ;

Pirila, Laura ;

Puolakka, Kari ;

Uusitalo, Tea ;

Blom, Marja ;

Konttinen, Yrjo Tapio ;

Nordstrom, Dan .

JOURNAL OF RHEUMATOLOGY, 2015, 42 (03) :372-378

[3] Considerations on treatment recommendations for rheumatoid arthritis [J].

Abud-Mendoza, Carlos .

REUMATOLOGIA CLINICA, 2015, 11 (04) :193-195

[4]

Alvarez-Hernández E, 2012, REUMATOL CLIN, V8, P168, DOI [10.1016/j.reumae.2012.06.018, 10.1016/j.reuma.2012.05.002]

[5]

[Anonymous], ARTHRITIS RES THER

[6]

[Anonymous], Rheumatology International

[7]

[Anonymous], 2012, Clin Rheumatol

[8]

[Anonymous], 2012, CLIN GUID DEV METH

[9]

[Anonymous], J RHEUMATOL

[10] Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison [J].

Baji, Petra ;

Pentek, Marta ;

Czirjak, Laszlo ;

Szekanecz, Zoltan ;

Nagy, Gyoergy ;

Gulacsi, Laszlo ;

Brodszky, Valentin .

EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 :S53-S64

← 1 2 3 4 5 6 7 8 9 10 →